SCHEMBL7256571

SCHEMBL7256571

Cc1cc2c(N)n[nH]c2nc1-c1ccc(O)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 5/20 0.58
▸ GSK3B P49841 5/20 0.58
▸ MAPK1 P28482 2/20 0.46
▸ MAP2K4 P45985 2/20 0.46
▸ MAPKAPK2 P49137 2/20 0.46
▸ MAPK6 Q16659 2/20 0.46
▸ MAPKAPK3 Q16644 1/20 0.46
▸ MAPKAPK5 Q8IW41 1/20 0.46
▸ FGFR1 P11362 2/20 0.43
▸ FGFR2 P21802 2/20 0.43
▸ PDPK1 O15530 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43
▸ RPS6KA3 P51812 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ CDK2 P24941 2/20 0.41
▸ TNIK Q9UKE5 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ USP7 Q93009 1/20 0.40
▸ ALK Q9UM73 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7257484 0.83 KDM4E (0.46) GSK3AGSK3BMAPK1
SCHEMBL7256564 0.82 GSK3A (0.58) GSK3AGSK3BMAPK1MAP2K4MAPKAPK2
SCHEMBL1555312 0.79 IKBKB (0.48) GSK3AGSK3BFGFR1FGFR2PDPK1
SCHEMBL10334229 0.72 PDE3B (0.50) GSK3AGSK3BRPS6KA3CDK2CYP3A4
SCHEMBL7261268 0.71 GSK3A (0.54) GSK3AGSK3BMAPK1FGFR1PDPK1
SCHEMBL13329422 0.70 ALDH1A1 (0.40) GSK3AGSK3BMAPK1MAP2K4MAPKAPK2
SCHEMBL26675449 0.70 JAK2 (0.44) GSK3AGSK3BMAPK1MAP2K4FGFR1
SCHEMBL10333628 0.69 ILK (0.42) GSK3AGSK3BHSP90AB1CDK2
SCHEMBL1056975 0.69 ALDH1A1 (0.49) GSK3AGSK3BMAPK1MAP2K4MAPKAPK2
SCHEMBL25366182 0.68 GAA (0.58) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003068773-A1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-08-21 — — WO disclosed
Send feedback